<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Lanatoside C anticancer mechanisms &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/lanatoside-c-anticancer-mechanisms/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 17 Oct 2025 12:52:17 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Lanatoside C anticancer mechanisms &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Lanatoside C: A New Cancer Treatment?</title>
		<link>https://bioengineer.org/lanatoside-c-a-new-cancer-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 17 Oct 2025 12:52:02 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[apoptosis induction in cancer therapy]]></category>
		<category><![CDATA[Drug repurposing in oncology]]></category>
		<category><![CDATA[Lanatoside C anticancer mechanisms]]></category>
		<category><![CDATA[molecular signaling pathways in cancer]]></category>
		<category><![CDATA[preclinical cancer treatment studies]]></category>
		<guid isPermaLink="false">https://bioengineer.org/lanatoside-c-a-new-cancer-treatment/</guid>

					<description><![CDATA[In the ongoing battle against cancer, where traditional drug development faces steep challenges such as prolonged timelines and exorbitant costs, innovative strategies have become imperative. An intriguing approach gaining momentum is drug repurposing, which identifies novel anticancer effects in existing FDA-approved drugs. Among these candidates, Lanatoside C—historically prescribed for cardiac conditions—is emerging as a compelling [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">282760</post-id>	</item>
	</channel>
</rss>
